These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 27191687)

  • 1. Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation.
    Gripp KW; Baker L; Kandula V; Conard K; Scavina M; Napoli JA; Griffin GC; Thacker M; Knox RG; Clark GR; Parker VE; Semple R; Mirzaa G; Keppler-Noreuil KM
    Am J Med Genet A; 2016 Oct; 170(10):2559-69. PubMed ID: 27191687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Causal somatic mutations in urine DNA from persons with the CLOVES subgroup of the PIK3CA-related overgrowth spectrum.
    Michel ME; Konczyk DJ; Yeung KS; Murillo R; Vivero MP; Hall AM; Zurakowski D; Adams D; Gupta A; Huang AY; Chung BHY; Warman ML
    Clin Genet; 2018 May; 93(5):1075-1080. PubMed ID: 29231959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
    Keppler-Noreuil KM; Sapp JC; Lindhurst MJ; Parker VE; Blumhorst C; Darling T; Tosi LL; Huson SM; Whitehouse RW; Jakkula E; Grant I; Balasubramanian M; Chandler KE; Fraser JL; Gucev Z; Crow YJ; Brennan LM; Clark R; Sellars EA; Pena LD; Krishnamurty V; Shuen A; Braverman N; Cunningham ML; Sutton VR; Tasic V; Graham JM; Geer J; Henderson A; Semple RK; Biesecker LG
    Am J Med Genet A; 2014 Jul; 164A(7):1713-33. PubMed ID: 24782230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine cell-free DNA is a biomarker for nephroblastomatosis or Wilms tumor in PIK3CA-related overgrowth spectrum (PROS).
    Biderman Waberski M; Lindhurst M; Keppler-Noreuil KM; Sapp JC; Baker L; Gripp KW; Adams DM; Biesecker LG
    Genet Med; 2018 Sep; 20(9):1077-1081. PubMed ID: 29300373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
    Keppler-Noreuil KM; Rios JJ; Parker VE; Semple RK; Lindhurst MJ; Sapp JC; Alomari A; Ezaki M; Dobyns W; Biesecker LG
    Am J Med Genet A; 2015 Feb; 167A(2):287-95. PubMed ID: 25557259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [PIK3CA-related overgrowth syndrome (PROS)].
    Venot Q; Canaud G
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S155-S156. PubMed ID: 28577738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pitfalls in the diagnosis of segmental overgrowth syndromes: a child with the c.2740G > A mutation in PIK3CA gene.
    Maguolo A; Antoniazzi F; Spano A; Fiorini E; Gaudino R; Mauro M; Cantalupo G; Biban P; Maitz S; Cavarzere P
    Ital J Pediatr; 2018 Sep; 44(1):110. PubMed ID: 30231930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
    Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
    Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations.
    Brouillard P; Schlögel MJ; Homayun Sepehr N; Helaers R; Queisser A; Fastré E; Boutry S; Schmitz S; Clapuyt P; Hammer F; Dompmartin A; Weitz-Tuoretmaa A; Laranne J; Pasquesoone L; Vilain C; Boon LM; Vikkula M
    Orphanet J Rare Dis; 2021 Jun; 16(1):267. PubMed ID: 34112235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
    Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
    Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic PIK3CA mutations in seven patients with PIK3CA-related overgrowth spectrum.
    Yeung KS; Ip JJ; Chow CP; Kuong EY; Tam PK; Chan GC; Chung BH
    Am J Med Genet A; 2017 Apr; 173(4):978-984. PubMed ID: 28328134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sonographic screening for Wilms tumor in children with CLOVES syndrome.
    Peterman CM; Fevurly RD; Alomari AI; Trenor CC; Adams DM; Vadeboncoeur S; Liang MG; Greene AK; Mulliken JB; Fishman SJ
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28627003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
    Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
    Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Pagliazzi A; Oranges T; Traficante G; Trapani C; Facchini F; Martin A; Semeraro A; Perrone A; Filippeschi C; Giglio S
    Front Pediatr; 2021; 9():732836. PubMed ID: 34568242
    [No Abstract]   [Full Text] [Related]  

  • 15. Low risk of embryonic and other cancers in PIK3CA-related overgrowth spectrum: Impact on screening recommendations.
    Faivre L; Crépin JC; Réda M; Nambot S; Carmignac V; Abadie C; Mirault T; Faure-Conter C; Mazereeuw-Hautier J; Maza A; Puzenat E; Collonge-Rame MA; Bursztejn AC; Philippe C; Thauvin-Robinet C; Chevarin M; Abasq-Thomas C; Amiel J; Arpin S; Barbarot S; Baujat G; Bessis D; Bourrat E; Boute O; Chassaing N; Coubes C; Demeer B; Edery P; El Chehadeh S; Goldenberg A; Hadj-Rabia S; Haye D; Isidor B; Jacquemont ML; Van Kien PK; Lacombe D; Lehalle D; Lambert L; Martin L; Maruani A; Morice-Picard F; Petit F; Phan A; Pinson L; Rossi M; Touraine R; Vanlerberghe C; Vincent M; Vincent-Delorme C; Whalen S; Willems M; Marle N; Verkarre V; Devalland C; Devouassoux-Shisheboran M; Abad M; Rioux-Leclercq N; Bonniaud B; Duffourd Y; Martel J; Binquet C; Kuentz P; Vabres P
    Clin Genet; 2023 Nov; 104(5):554-563. PubMed ID: 37580112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA.
    Luks VL; Kamitaki N; Vivero MP; Uller W; Rab R; Bovée JV; Rialon KL; Guevara CJ; Alomari AI; Greene AK; Fishman SJ; Kozakewich HP; Maclellan RA; Mulliken JB; Rahbar R; Spencer SA; Trenor CC; Upton J; Zurakowski D; Perkins JA; Kirsh A; Bennett JT; Dobyns WB; Kurek KC; Warman ML; McCarroll SA; Murillo R
    J Pediatr; 2015 Apr; 166(4):1048-54.e1-5. PubMed ID: 25681199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS).
    Martinez-Lopez A; Blasco-Morente G; Perez-Lopez I; Herrera-Garcia JD; Luque-Valenzuela M; Sanchez-Cano D; Lopez-Gutierrez JC; Ruiz-Villaverde R; Tercedor-Sanchez J
    Clin Genet; 2017 Jan; 91(1):14-21. PubMed ID: 27426476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of 13 patients with PIK3CA-related overgrowth spectrum using a targeted deep sequencing approach.
    de Kock L; Cuillerier A; Gillespie M; Couse M; Hartley T; Mears W; Bernier FP; Chudley AE; Frosk P; Nikkel SM; Innes AM; Lauzon J; Thomas M; Guerin A; Armour CM; Weksberg R; Scott JN; Watkins D; Harvey S; Cytrynbaum C; ; Kernohan KD; Boycott KM
    Am J Med Genet A; 2024 Mar; 194(3):e63466. PubMed ID: 37949664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic and molecular characterization of five patients with PIK3CA-related overgrowth spectrum (PROS).
    Gökpınar İli E; Taşdelen E; Durmaz CD; Altıner Ş; Tuncalı T; Martinez-Glez V; Karabulut HG; Vural S; Ceylaner S; Acar MO; Ilgın Ruhi H
    Am J Med Genet A; 2022 Jun; 188(6):1792-1800. PubMed ID: 35238469
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.